Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 31, 2008, Pages 10895-10900

  Takeda, Kazuyoshi ^a,b   Kojima, Yuko ^a   Ikejima, Kenichi ^a   Harada, Kenichi ^c   Yamashina, Shunhei ^a   Okumura, Kyoko ^a   Aoyama, Tomonori ^a   Frese, Steffen ^d   Ikeda, Hiroko ^c   Haynes, Nicole M ^b   Cretney, Erika ^b   Yagita, Hideo ^a   Sueyoshi, Noriyoshi ^a   Sato, Nobuhiro ^a   Nakanuma, Yasuni ^c   Smyth, Mark J ^b   Okumura, Ko ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

Cholangitis; Primary sclerosing cholangitis

Indexed keywords

DEATH RECEPTOR 5; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DEATH RECEPTOR 5;

ANIMAL CELL; APOPTOSIS; ARTICLE; BILE DUCT LIGATION; COMMON BILE DUCT; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER CELL; LIVER INJURY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; CELL LINE, TUMOR; CHOLANGITIS; CHOLESTASIS; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, MUTANT STRAINS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND;

MUS;

EID: 49449097533     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0802702105     Document Type: Article

References (43)

1. Aggarwal BB, Shishodia S, Ashikawa K, Bharti AC (2002) The role of TNF and its family members in inflammation and cancer: lessons from gene deletion. Current Drug Targets 1:327-341.
2. Locksley RM, Killeen N, Lenardo MJ (2001) The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104:487-501.
3. Ashkenazi A (2002) Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2:420-430.
4. + T-cell memory via TRAIL-mediated activation-induced cell death. Nature 434:88-93.
5. + T cells. Nat Immunol 7:475-481.
6. H2 cells and the expression of allergic airway disease. Nat Med 13:1308-1315.
7. Takeda K, et al. (2001) Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 7:94-100.
8. Takeda K, et al. (2002) Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 195:161-169.
9. Takeda K, Stagg J, Yagita H, Okumura K, Smyth MJ (2007) Targeting death-inducing receptors in cancer therapy. Oncogene 26:3745-3757.
10. Ashkenazi A, et al. (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104:155-162.
11. Walczak H, et al. (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5:157-163.
12. Chuntharapai A, et al. (2001) Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol 166:4891-4898.
13. Ichikawa K, et al. (2001) Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 7:954-960.
14. Takeda K, et al. (2004) Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med 199:437-448.
15. Tolcher AW, et al. (2007) Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 25:1390-1395.
16. Plummer R, et al. (2007) Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res 13:6187-6194.
17. Kondo T, Suda T, Fukuyama H, Adachi M, Nagata S (1997) Essential roles of the Fas ligand in the development of hepatitis. Nat Med 3:409-413.
18. Jo M, et al. (2000) Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 6:564-567.
19. Lawrence D, et al. (2001) Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 7:383-385.
20. Mori E, et al. (2004) Human normal hepatocytes are susceptible to apoptosis signal mediated by both TRAIL-R1 and TRAIL-R2. Cell Death Differ 11:203-207.
21. Volkmann X, et al. (2007) Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver. Hepatology 46:1498-1508.
22. Bataller R, Brenner DA (2005) Liver fibrosis. J Clin Invest 115:209-218.
23. Lee YM, Kaplan MM (2002) Management of primary sclerosing cholangitis. Am J Gastroenterol 97:528-534.
24. Levy C, Lindor KD (2003) Current management of primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 38 Suppl 1:S24-S37.
25. Cho WK, Mennone A, Boyer JL (2001) Isolation of functional polarized bile duct units from mouse liver. Am J Physiol Gastrointest Liver Physiol 280:G241-G246.
26. Yin XM, et al. (1999) Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 400:886-891.
27. Werner AB, de Vries E, Tait SWG, Bontjer I, Borst J (2002) TRAIL receptor and CD95 signal to mitochondria via FADD, caspase-8/10, Bid, and Bax but differentially regulate events downstream from truncated Bid. J Biol Chem 277:40760-40767.
28. Ricci MS, et al. (2004) Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol 24:8541-8555.
29. Zheng SJ, Wang P, Tsabary G, Chen YH (2004) Critical roles of TRAIL in hepatic cell death and hepatic inflammation. J Clin Invest 113:58-64.
30. Hao C, et al. (2004) TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. Cancer Res 64:8502-8506.
31. Gores GJ, Kaufmann SH (2001) Is TRAIL hepatotoxic? Hepatology 34:3-6.
32. Higuchi H, Bronk SF, Taniai M, Canbay A, Gores GJ (2002) Cholestasis increases tumor necrosis factor-related apoptotis-inducing ligand (TRAIL)-R2/DR5 expression and sensitizes the liver to TRAIL-mediated cytotoxicity. J Pharmacol Exp Ther 303:461-467.
33. Kahraman A, et al. (2008) TRAIL mediated liver injury by the innate immune systems in the bile duct-lagated mice. Hepatology 47:1317-1330.
34. LaRusso NF, et al. (2006) Primary sclerosing cholangitis: summary of a workshop. Hepatology 44:746-764.
35. + gut-homing lymphocytes to the liver in primary sclerosing cholangitis. J Exp Med 200:1511-1517.
36. Baccala R, Kono DH, Theofilopoulos AN (2005) Interferons as pathogenic effectors in autoimmunity. Immunol Rev 204:9-26.
37. Kayagaki N, et al. (1999) Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. J Exp Med 189:1451-1460.
38. Fulda S, Debatin KM (2002) IFNγ sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway. Oncogene 21:2295-2308.
39. Harada K et al. (2007) Innate immune response to double-stranded RNA in biliary epithelial cells is associated with the pathogenesis of biliary atresia. Hepatology 46:1146-1154.
40. Xu B, Broome U, Ericzon BG, Sumitran-Holgersson S (2002) High frequency of autoantibodies in patients with primary sclerosing cholangitis that bind biliary epithelial cells and induce expression of CD44 and production of interleukin 6. Gut 51:120-127.
41. Ishimura N, Isomoto H, Bronk SF, Gores GJ (2006) Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am J Physiol Gastrointest Liver Physiol 290:G129-G136.
42. Musallam L, Ethier C, Haddad PS, Bilodeau M (2001) Role of EGF receptor tyrosine kinase activity in antiapoptotic effect of EGF on mouse hepatocytes. Am J Physiol Gastrointest Liver Physiol 280:G1360-G1369.
43. Katayanagi K, Kono N, Nakanuma Y (1998) Isolation, culture and characterization of biliary epithelial cells from different anatomical levels of the intrahepatic and extrahepatic biliary tree from a mouse. Liver 18:90-98.